bpc 157 & 1500 BPC-157 Injectable Peptide for Healing

minimal systemic safety data available Learn More Which Peptide for Which Application

Also, avoid rubber-closure vials, as they allow contamination through their hole and from rubber additives

- Gastric pentadecapeptide body protection compound BPC 157 and

Molecular Composition and Characteristics Component 1: BPC-157 (synthetic pentadecapeptide) Component 2: TB-500 (thymosin beta-4 analogue) Component 3: KPV (tripeptide fragment of alpha-MSH) Component 4: GHK-Cu (copper tripeptide complex) Structure: Linear synthetic peptide chains supplied as a blended formulation Dose Format: High-concentration 80mg blended vial Stability and Storage Guidelines Supplied as a lyophilized powder for enhanced long-term stability Recommended storage temperature: 20C or below Protect from moisture, humidity, and prolonged light exposure Avoid repeated freezethaw cycles Reconstituted solutions remain stable for approximately 2448 hours under refrigeration Solubility and Reconstitution Options Bacteriostatic water Sterile saline solutions Acidic buffer systems Compatible organic analytical solvents Technical Specifications product Name Klow Blend (BPC-157 + TB-500 + KPV + GHK-Cu) 80mg cas 137525-51-0, 77591-33-4, 112965-21-6, 89030-95-5 purity 99% (HPLC verified) unit Size 80 mg blended vial form Lyophilized peptide powder synthesis Solid-Phase Peptide Synthesis (SPPS) analytical HPLC, Mass Spectrometry, UV Spectrophotometry molecular Structure Linear synthetic peptide blend stability High when stored under recommended laboratory conditions Analytical Validation and Quality Assurance HPLC purity confirmation Mass Spectrometry molecular identity verification UV spectrophotometric concentration analysis Batch-to-batch consistency verification Endotoxin and microbial contamination screening Regulatory and Compliance Statement The BioPeptides Klow Blend 80mg is supplied strictly for laboratory research and scientific investigation

More than eighty types of autoimmune disorders exist, such as rheumatoid arthritis, lupus, multiple sclerosis, and type 1 diabetes

In this regard, it is interesting to note that ARA 290 was observed to reverse neuropathic changes in the sympathetic ganglia of a mouse model of type 2 diabetes (27)